Marc Damelin is Executive Director, Head of Biology at Mersana Therapeutics, where he is focused on ADC discovery and development for oncology. Prior, he spent 10 years at Pfizer, where he led ADC discovery teams, oversaw the ADC portfolio and mentored two postdoctoral fellows. He is the Editor of the book “Innovations for Next-Generation Antibody-Drug Conjugates” published…Read more